Biotherapeutics continue to revolutionize how clinicians treat many human diseases. Protein therapies using molecules like peptides and monoclonal antibodies have become well established in the clinic ...

Subvisible particles have the potential to impact efficacy, safety, and regulatory compliance throughout the field of biotherapeutics. Conventional particle analysis methods only provide particle ...

Protein-based therapeutics have transformed treatments for numerous diseases, yet their production remains highly complex and cost-intensive [1][2],[3][4]. Downstream processing (DSP), including ...

Navigating the development and manufacturing of biopharmaceuticals is complex, especially when it comes to ensuring that drug formulations are stable and effective. A key challenge lies in detecting ...

Emerging biologics such as multispecific antibodies, mRNA vaccines, and viral vector–based gene therapies are more complex than established biologics such as monoclonal antibodies and recombinant ...

Subvisible particulate matter is under increasing amounts of scrutiny in the field of parenteral and ophthalmic drug products. USP <1788> and <1788.3> explicitly recommend the use of flow imaging and ...

New flow imaging microscopy technology visualizes a broad range of subvisible particles hidden in therapeutic suspensions. These fluttering sensations are the brain’s reaction to certain emotions, ...

Single-particle optical sensing (SPOS) was originally developed for the field of particulate contamination analysis. Particles in a liquid suspension flow through a small "photozone", a narrow, ...

At Yokogawa Fluid Imaging Technologies our mission is to bring clarity and focus to the study of subvisible particles in the life sciences. With our FlowCam technology, we are committed to developing ...